1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Pramipexole |
| brand | String | Mirapex (IR), Mirapex ER |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] • [[:Category:Antiparkinsonians|Antiparkinsonian]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' |
| starting_dose | String | Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed |
| preparations | String | IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg |
| fda_max | String | 4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Motor improvement over days at therapeutic dose |
| duration | String | TID dosing (IR); once-daily (ER) |
| halflife | String | 8-12 hours (longer in elderly and renal impairment)'"`UNIQ--ref-0000001B-QINU`"' |
| bioavailability | String | >90% (oral)'"`UNIQ--ref-0000001C-QINU`"' |
| pregnancy | String | Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
